JP2006502203A - 筋肉損傷を監視し診断するための単離した翻訳後修飾タンパク質 - Google Patents

筋肉損傷を監視し診断するための単離した翻訳後修飾タンパク質 Download PDF

Info

Publication number
JP2006502203A
JP2006502203A JP2004542122A JP2004542122A JP2006502203A JP 2006502203 A JP2006502203 A JP 2006502203A JP 2004542122 A JP2004542122 A JP 2004542122A JP 2004542122 A JP2004542122 A JP 2004542122A JP 2006502203 A JP2006502203 A JP 2006502203A
Authority
JP
Japan
Prior art keywords
troponin
phosphorylated
protein
serine
translationally modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004542122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502203A5 (enExample
Inventor
エイク ジェニファー イー． バン
ジェレミー エー． シー． シンプソン
ニネッタ ブシェーミ
マイケル ケイ． クイック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen's University
Original Assignee
Queen's University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen's University filed Critical Queen's University
Publication of JP2006502203A publication Critical patent/JP2006502203A/ja
Publication of JP2006502203A5 publication Critical patent/JP2006502203A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
JP2004542122A 2002-10-11 2003-10-10 筋肉損傷を監視し診断するための単離した翻訳後修飾タンパク質 Withdrawn JP2006502203A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/270,838 US7196169B2 (en) 2002-10-11 2002-10-11 Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
PCT/CA2003/001523 WO2004034060A2 (en) 2002-10-11 2003-10-10 Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage

Publications (2)

Publication Number Publication Date
JP2006502203A true JP2006502203A (ja) 2006-01-19
JP2006502203A5 JP2006502203A5 (enExample) 2006-11-30

Family

ID=32069017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004542122A Withdrawn JP2006502203A (ja) 2002-10-11 2003-10-10 筋肉損傷を監視し診断するための単離した翻訳後修飾タンパク質

Country Status (6)

Country Link
US (1) US7196169B2 (enExample)
EP (1) EP1554587A2 (enExample)
JP (1) JP2006502203A (enExample)
AU (1) AU2003273674A1 (enExample)
CA (1) CA2501756C (enExample)
WO (1) WO2004034060A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207301B2 (en) 2007-06-20 2012-06-26 Nec Corporation Hepatocellular carcinoma protein marker

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618782B1 (en) 1999-10-18 2009-11-17 Queen's University At Kingston Methods of diagnosing muscle damage
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
CA2419295A1 (en) * 2000-08-21 2002-02-28 Queen's University At Kingston Methods and kits for separation and detection of proteins in biological samples
DK1571970T3 (da) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
WO2005113798A2 (en) * 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
EP2097750A2 (en) * 2006-10-26 2009-09-09 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
CN1974594B (zh) * 2006-11-16 2010-04-14 中国人民解放军军事医学科学院卫生学环境医学研究所 人心肌肌钙蛋白ⅰ亚基核酸适配子及应用
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP3178846B1 (en) * 2010-02-17 2018-08-22 Cedars-Sinai Medical Center Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2013085367A1 (en) * 2011-12-09 2013-06-13 Kyungpook National University Industry-Academic Cooperation Foundation Cardiac troponin i-targeting peptide and use thereof
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
CN111662909B (zh) * 2019-03-05 2022-07-15 中国科学技术大学 心肌肌钙蛋白i特异性核酸适配体及其应用
BR102021020613A2 (pt) * 2021-10-14 2023-04-18 Universidade Federal Do Rio De Janeiro Método de investigação proteômica em amostra para diagnóstico da rabdomiólise e kits para realização do mesmo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689777B2 (en) 1993-05-17 1998-04-09 Fortron Bioscience, Inc. Assay for cardiac troponin I
US5702905A (en) 1994-09-28 1997-12-30 Spectral Diagnostics Monoclonal antibody to human ventricular myosin light chains
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
US6227658B1 (en) 1997-06-23 2001-05-08 Kabushiki Kaisha Toshiba Apparatus and method for forming thin film using ink-jet mechanism
US7384751B1 (en) 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
US6248546B1 (en) * 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207301B2 (en) 2007-06-20 2012-06-26 Nec Corporation Hepatocellular carcinoma protein marker

Also Published As

Publication number Publication date
US7196169B2 (en) 2007-03-27
WO2004034060A2 (en) 2004-04-22
EP1554587A2 (en) 2005-07-20
WO2004034060A3 (en) 2005-03-03
AU2003273674A1 (en) 2004-05-04
CA2501756C (en) 2013-01-29
CA2501756A1 (en) 2004-04-22
US20040072255A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
US7196169B2 (en) Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
Bodor et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue
CN102460174B (zh) 使用一组新型低丰度人类血浆蛋白生物标记对肝纤维化进行临床诊断
US20120052592A9 (en) Method for determining prognosis of acute central nervous system disorder
JP2010525362A (ja) 免疫調節剤のスクリーニング方法
JP7492711B2 (ja) アルツハイマー病バイオマーカー
RU2721690C2 (ru) Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии
JP2005528588A (ja) シヌクレイン関連疾患の検出および／またはモニタリング
US20090148860A1 (en) Methods of diagnosing muscle damage
CN114573692B (zh) 用于检测嗜铬粒蛋白a的免疫测定与抗体
KR20140045409A (ko) 초기 류마티스성 관절염의 진단 방법
AU2001287423B2 (en) Methods and kits for separation and detection of proteins in biological samples
US20100129851A1 (en) Methods of diagnosing muscle damage
JP2000512123A (ja) ネフロパシー―関連免疫グロブリンｇ及びそのための抗体
CN108139404A (zh) 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测
EP3203240B1 (en) Method for determining acute myocardial infarction
JP2024526081A (ja) 敗血症及び敗血症性ショックを予測する方法
US9182413B2 (en) Methods and devices for diagnosing cardiac disorders
JP2019190883A (ja) 新規肺がんマーカー
US20130078653A1 (en) Antibodies, compositions, and assays for detection of cardiac disease
JP6970975B2 (ja) ＩｇＧ４関連疾患の検査方法
HK40115326A (en) Novel assay and novel methods of treating hutchinson-gilford progeria syndrome
JP6799863B2 (ja) 心疾患または筋疾患の診断薬
CN106459166B (zh) 检测肉瘤转移的方法和生物标记物
CN118511076A (zh) 新分析方法和治疗哈钦森-吉尔福德早衰综合征的新方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061010

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080324